Drug Discovery. Accelerated.
IMPROVING HEALTH THROUGH COMPUTATION
YEARS INTO MINUTES
It can take up to six years to build up a body of evidence to support a new drug candidate for commercial development. That’s a long time.
At twoXAR, we are turning those years into minutes. Whether we are using your data to generate new drug candidates for a specific disease or assessing the efficacy of existing therapeutics, we can help.
Using big data and patent-pending algorithms, we radically reduce the time it takes to find new drug candidates and assess their efficacy. Using our DUMA™ Drug Discovery platform we evaluate large public and proprietary datasets to identify and rank high probability drug-disease matches orders of magnitude faster than wet-lab approaches. These matches can be used to cross-validate clinical research, repurpose existing medicines, or identify novel drug candidates for further clinical testing.
Fast: typical engagement is from handshake to predictions in less than six months
Scalable: process data sets of any size in minutes using an elastic computing environment
Unbiased: predictions are based on statistical modeling – you control the amount of human input
Comprehensive: works with gene expression, protein-interaction, chemical structure, MOA, and clinical data, among others – it even handles noisy or incomplete assays
Agnostic: models work with any disease and have been tested on more than 20 diseases to date
User-friendly: predictions are summarized in easy-to-read PDF reports
No capex: service model requires no software license fees or local hardware installations
Want to learn more about DUMA™ and how it worked in disease-specific case studies? Connect.
WHO WE ARE
twoXAR's founders share more than a name, they share a commitment to disrupting the drug discovery process and accelerating the development of new medicines for rare and common health conditions. They are supported by a team of experts in data science and systems biology and a network of advisers that includes biopharmaceutical industry and clinical research veterans.
Andrew A. Radin
CEO & Co-Founder
Prior to co-founding twoXAR, Andrew held Chief Technology Officer roles at several early stage companies where he managed teams as large as a hundred technologists distributed around the world. Andrew developed the company's proprietary algorithm and as Chief Executive Officer is focused on overall company strategy, product development and fundraising.
Andrew studied biomedical informatics in Stanford University's SCPD graduate program and holds Master of Science and Bachelor of Science degrees in computer science from Rochester Institute of Technology.
Andrew M. Radin
CBO & Co-Founder
Andrew M. Radin formerly worked as an investor in venture and private equity funds and has designed, built, and managed several small organizations. Andrew co-founded a mobile platform startup while at MIT. As Chief Business Officer of twoXAR, Andrew is focused on validating the market, identifying customers, building the team, and fundraising.
Andrew holds a Master in Business Administration degree from MIT Sloan, a Bachelor of Science degree in biochemistry and cell biology from UCSD, and a Bachelor of Arts degree in economics from UCSD.
by: Andrew M. Radin
Chief Business Officer, twoXAR
The short-list for the annual Arthur C. Clarke Award was recently announced and it reminded me of a post we did last fall on augmentation vs. automation. Clarke is a British science fiction writer who is famous for being the co-screenplay writer (with Stanley Kubrick) of the 1968 film 2001: A Space Odyssey. He is also known for the so-called Clarke’s Laws, which are three ideas intended to guide consideration of future scientific developments... read post here.
Guest post by Marina Sirota, PhD, twoXAR Advisor and Assistant Professor, UCSF Institute for Computational Health Sciences
Earlier this month, Andrew A. Radin and I had the opportunity to attend a community outreach meeting at UC Irvine hosted by the NIH Libraries of Cellular Signatures (LINCS) consortium. It was a great and diverse community gathering of drug discovery researchers from academia, biopharma, startups, consulting companies and government funding agencies. For anyone interested in listening to the talks, some of them have been posted on YouTube.
The focus of day one was to review the progress to date on collaborations among researchers spearheading projects that are exploring... read post here.